EMA Grants PRIME Designation to TolerogenixX’s MIC-Lx Therapy for Donor-Specific Immune Tolerance in Kidney Transplantation

AI Briefing

• – EMA grants PRIME designation for TolerogenixX's MIC-Lx therapy for kidney transplantation
• – TolerogenixX's MIC-Lx therapy supports sustained safety and reduced immunosuppression with up to 10-year follow-up data
• – therapy aimed at inducing donor-specific immune tolerance